Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes

Summary

The trial used a randomized, double-blind, placebo-controlled, superior-effect design, multicenter clinical study. The trial was divided into a test group and a placebo group,the two groups were randomized in a 1:1 ratio and planned to enroll 240 patients with type 2 diabetes. After 2 weeks of screening, all subjects entered the treatment period,which was 24 weeks, and 1 week period of follow-up.

Timeline

Start

2019-07-08

Primary completion

2020-12-03

Completion

2020-12-28

Drugs

Indications